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At the start of the 20th century, CO poisoning was treated by administering a combination
of CO2 and O2 (carbogen) to stimulate ventilation. This treatment was reported to be highly
effective, even reversing the deep coma of severe CO poisoning before patients arrived at
the hospital. The efﬁcacy of carbogen in treating CO poisoning was initially attributed to the
absorptionofCO2;however,itwaseventuallyrealizedthattheincreaseinpulmonaryventilation
was the predominant factor accelerating clearance of CO from the blood. The inhaled CO2 in
the carbogen stimulated ventilation but prevented hypocapnia and the resulting reductions
in cerebral blood ﬂow. By then, however, carbogen treatment for CO poisoning had been
abandonedinfavourofhyperbaricO2.Now,ahalf-centurylater,thereisaccumulatingevidence
thathyperbaricO2 isnotefﬁcacious,mostprobablybecauseofdelaysininitiatingtreatment.We
nowalsoknowthatincreasesinpulmonaryventilationwithO2-enrichedgascanclearCOfrom
the blood as fast, or very nearly as fast, as hyperbaric O2.C o m p a r e dw i t hh y p e r b a r i cO 2,t h e
technology for accelerating pulmonary clearance of CO with hyperoxic gas is not only portable
and inexpensive, but also may be far more effective because treatment can be initiated sooner.
In addition, the technology can be distributed more widely, especially in developing countries
where the prevalence of CO poisoning is highest. Finally, early pulmonary CO clearance does
notdelayorprecludeanyothertreatment,includingsubsequent treatmentwithhyperbaricO2.
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Background
At the turn of the 20th century, CO poisoning was treated
byadministeringhighconcentrationsofO2 toincreasethe
O2 carried in the blood and, if necessary, ventilation was
stimulated by adding CO2. It was initially and mistakenly
thought that patients asphyxiated to unconsciousness
by CO had a total body deﬁcit of CO2 that was
replenished by the inhaled CO2 (Henderson etal. 1921).
Furthermore, animal tests had shown that the addition
of CO2 to O2 markedly increased the dissociation of
carboxyhaemoglobin (COHb) and accelerated clearance
of CO compared with using O2 alone (Henderson &
Haggard, 1920). Carbon dioxide was administered in
concentrations of 5–10% in O2, known as ‘carbogen’.
From the very beginning, treatment of CO-poisoned
patients with carbogen at the site of rescue led to reports
of dramatic reversals of coma and other neurological
symptoms (Henderson & Haggard, 1922). In short order,
the administration of carbogen became the standard of
care for CO poisoning, and remained so for almost a half-
century. Indeed, carbogen remains a stock item in many
hospitals to this day.
Hyperbaric oxygen
By the 1960s, the rationale for using carbogen for CO
poisoning was increasingly questioned (Donald & Paton,
1955). The notion that CO poisoning was accompanied
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by a deﬁcit of CO2 was rejected (Donald & Paton,
1955). Ventilatory stimulation by CO2 was no longer
required, because hypoventilation accompanying coma
could be managed by endotracheal intubation and
mechanical ventilation. It became feasible to increase CO
dissociation from haemoglobin (Hb) by exploiting the
mass action effect of O2 on the equilibrium (Haldane,
1895) COHb+O2
←
→O2Hb+CO by administering the
O2 at hyperbaric pressures (Pace etal. 1950). Hyperbaric
O2 replaced carbogen as the preferred treatment (Smith,
1962)becauseitwasthought(mistakenly,assubsequently
demonstrated; Fisher etal. 1999) to result in faster
CO elimination (Norman & Ledingham, 1967) and,
on theoretical grounds, to be effective at reversing
the assumed toxic effects of CO in such extravascular
tissues as the brain (Brown & Piantadosi, 1990; Stoller,
2007).
Time to treatment over type of treatment
The point cannot be too strongly emphasized that for
treatment to be effective it must be applied at the earliest
possible moment after the victim is discovered, and must
remove the carbon monoxide from his blood as soon as
possible. (Henderson & Haggard, 1922)
Although the physics and chemistry underpinning the
effectiveness of hyperbaric O2 in clearing CO from the
blood are unassailable, and some beneﬁcial effects can
be demonstrated in animals (Brown & Piantadosi, 1990,
1992; Piantadosi etal. 1997), in practice it has been
difﬁcult to demonstrate its clinical efﬁcacy. The poor
response of most victims of CO poisoning to hyperbaric
O2 has been conﬁrmed repeatedly by expert panels in
Australia, Canada and the USA (Buckley etal. 2005;
Juurlink etal. 2005; McMaster University Division of
Emergency Medicine, 2006; Wolf etal. 2008), as well as
largecontrolledtrialsinAustralia(Scheinkesteletal.1999)
and France (Annane etal. 2010). The primary lesson to
be learned from the discrepancies between animal and
clinical studies is that for patients poisoned by CO, the
time to treatment, rather than the method of treatment,
is of major importance (Gorman etal. 1992; Scheinkestel
etal. 1999). Even from the very beginning of hyperbaric
O2 treatment of CO poisoning in Glasgow, it was clear
that delays between poisoning and treatment markedly
reduceditseffectiveness(Smith,1962).Timestotreatment
as short as 3–6h, which are all that can be expected
for hyperbaric O2 given the logistics of patient transport
and chamber preparation, continue to show no beneﬁt
compared with normobaric O2 (Scheinkestel etal. 1999;
Annane etal. 2010).
Effect of time to treatment on pathology of CO
poisoning
It has been long understood that ‘asphyxia is not
immediately terminated when the victim is removed
from the gassing chamber...although his body may be
surrounded and his lungs ﬁlled with fresh air, his brain
continues to be asphyxiated’ (Henderson & Haggard,
1922). Eventually, there is a redistribution of CO from
bloodtoextravasculartissues(Coburn,1970),drawnthere
bythehighafﬁnityofsomecellularmoleculesforCO[e.g.
myoglobin in heart muscle (Coburn, 1970; Dolan, 1985)
andcytochromesinthebrain(Cronjeetal.2004)],evenat
low [COHb], and particularly with hypoxaemia (Dolan,
1985).
OneinstructivemodelofCOdistributionkineticstoan
extravascular compartment is CO in the fetus, as studied
by Longo and colleagues (Hill etal. 1977; Longo & Hill,
1977) in pregnant sheep. Fetal Hb has a higher afﬁnity
for both O2 and CO than maternal Hb. After an initial
maternalexposuretoCO,thereisadelayinthetransferof
CO to the fetus of about 1h (Longo & Hill, 1977), which
is characteristic of many tissues (Cronje etal. 2004). This
delay is due to the low partial pressure of CO (PCO)i n
the plasma, because it is tightly bound to Hb (Bruce etal.
2008). Eventually, at higher [COHb], PCO rises and CO
begins to diffuse into the tissues. At equilibrium, fetal
[COHb] will exceed maternal [COHb] (dotted lines in
Fig.1). If rescue occurs prior to equilibration of CO,
maternal[COHb]willfollowthetimecourseillustratedin
Fig.1.IfnormobaricO2isadministered,thematernalhalf-
time of CO elimination will be ∼80min (Dolan, 1985).
However, because of the greater afﬁnity of fetal Hb for
CO, fetal [COHb] will continue to rise and so exceed
Figure 1. Schematic diagram illustrating the kinetics of [COHb]
in mother (red) and fetus (teal) after 3 h exposure to CO and
then rescue
Black dotted lines represent [COHb] at equilibrium; coloured dashed
lines represent [COHb] with normobaric O2 treatment; coloured
dotted lines represent [COHb] with accelerated CO clearance. (Figure
from Rucker & Fisher, 2006, with permission. Labels added to original
ﬁgure by the authors.)
C   2011 The Authors. Journal compilation C   2011 The Physiological Society1264 J. A. Fisher and others Exp Physiol 96.12 pp 1262–1269
that of the mother, even as her [COHb] is falling. If CO
clearancefromthemotherisaccelerated,thePCO gradient
between the fetus and mother increases (Longo & Hill,
1977),therebyalsoincreasingtherateofeliminationfrom
the fetus. A computer simulation of CO kinetics between
mother and fetus using the model proposed by Hill &
Longo (1977) is available as a supplemental ﬁle entitled
CO Model.zip.
These principles of CO kinetics have long been
acknowledged(Henderson&Haggard,1922;Smith,1962;
Scheinkestel etal. 1999); yet somehow, by consensus,
a treatment that was highly effective because it could
be administered with the least delay (carbogen) was
abandoned for another (hyperbaric O2) despite its
associateddelayintreatment.The(presumed)greaterrate
Figure 2. Effect of poikilocapnic and isocapnic normobaric O2
treatment on cerebral O2 delivery (DO2) in CO-exposed human
subjects
Fourteen human subjects were exposed on two separate occasions to
CO until their [COHb] reached 10–12%. They were administered
100% O2 with, and without, maintaining isocapnia. Blood O2 delivery
was calculated from arterial PO2, arterial PCO2, haemoglobin
saturation (11–[COHb]), plasma O2 content, and changes in middle
cerebral artery ﬂow velocity (MCAV) as measured by transcranial
Doppler (as a surrogate of change in cerebral blood ﬂow).
Poikilocapnic hyperoxia resulted in a signiﬁcantly lower DO2. (From
Rucker et al. 2002, with permission from the publisher.)
of CO elimination and the potential of reversing CO-
related pathology (Sharp etal. 1962) with hyperbaric O2
was considered an acceptable trade-off for the difﬁcult
logistics, increased expense and added delay in treatment.
Despite little evidence of its value, hyperbaric O2 has
remained the mainstay of treatment for the last half a
century.
Is normobaric oxygen a standard of care?
Even normobaric O2 treatment of CO poisoning is
problematic. The effect of PO2 on the half-time of
[COHb] reduction in patients treated in hospital (as
opposed to laboratory volunteers) is highly unreliable
(r2 =0.19), ranging from 26 to 148min (Weaver etal.
2000). Furthermore, normobaric O2 treatment may even
contribute to the morbidity of CO poisoning. Apart from
the potential for free radical generation by hyperoxia
(Thom, 1990), there is also the underappreciated effect of
hyperoxia as a ventilatory stimulant. Hyperoxia-induced
hyperventilation results in some degree of hypocapnia
(Becker etal. 1996), which is associated with a reduction
of blood ﬂow in such CO2-responsive vascular beds as
the coronary (Case etal. 1975) and cerebral circulations.
The reduction in cerebral (Kety & Schmidt, 1948) blood
ﬂow with hypocapnia occurs even in the presence of
increasedlevelsofCOintheblood(Ruckeretal.2002).In
normoxic individuals, as well as those with high [COHb]
(Henderson & Haggard, 1922), normobaric O2 produces
only a very small increase in blood O2 content that is
carried in the plasma, where it is poorly soluble. If this
smallincreaseinbloodO2 contentisaccompaniedbyeven
a small reduction in tissue blood ﬂow, the result can be a
netreductioninorganO2delivery(Caseetal.1975;Rucker
etal. 2002). Figure2 illustrates that the administration
of normobaric O2, an undisputed treatment for CO
poisoning since the time of Haldane (Haldane, 1895),
may even exacerbate the brain ischaemia resulting from
CO poisoning.
Back to the future
If there are problems with carbogen, hyperbaric and
normobaric O2, where do we go from here?
Increased alveolar ventilation can be as effective as
hyperbaric O2
About a decade ago, the trade-offs between rate of CO
elimination and time to treatment were re-examined.
The initial studies compared the half-times of reduction
of [COHb] induced by increases in alveolar ventilation
with those resulting from hyperbaric O2. Previous studies
(Henderson & Haggard, 1920) had concentrated on the
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relative efﬁcacies of various mixtures of CO2 in O2 for
reducing [COHb] in spontaneously breathing animals
(Walton etal. 1925) and humans (Henderson & Haggard,
1922). In the early 1960s, it became apparent that the
elimination of rebreathing during assisted ventilation
(Douglas etal. 1961) and the magnitude of the minute
ventilation(Killick&Marchant,1959),i.e.thenetalveolar
ventilation, rather than the concentration of CO2 in the
carbogen, was the main factor determining the half-
time of elimination. Indeed, with controlled ventilation
Fisher etal. (1999) demonstrated, in dogs, that isocapnic
increases in alveolar ventilation result in the same half-
times of CO elimination as those for hyperbaric O2
(Fig.3).
Favourable CO kinetics with increased alveolar
ventilation
Takeuchi etal. (2000) then investigated CO elimination
half-times in spontaneously breathing human volunteers
exposed to CO. Subjects breathed O2 using a circuit
that maintained normocapnia. Several ﬁndings from this
study are of interest. First, the ventilatory response to
normobaric O2 (open symbols in Fig.4) varied between
subjects. Second, the relationship between elimination
half-times and minute ventilation is a rectangular
hyperbola. This shape means that initial graded increases
in minute ventilation above resting values result in the
Figure 3. Elimination half-times for [COHb]
Five anaesthetized, intubated, spontaneously breathing dogs were
exposed to CO until [COHb] reached ∼70%. They were then
administered, sequentially, room air (Air), normobaric O2 (NBO2)a n d
then vigorously mechanically ventilated with O2 while maintaining
normocapnia (IHO2). Blood was drawn every 5 min and analysed for
[COHb]. Plots of log [COHb] versus time were used to calculate the
half-times of reduction in [COHb]. Values are compared with dogs
prepared in a similar manner and treated with normocapnic ventilation
with O2 at 3 atm (304 kPa). Isocapnic hyperpnoea resulted in a similar
rate of [COHb] reduction to hyperbaric O2 (HBO2). Reprinted with
permission of the American Thoracic Society. Copyright C   American
Thoracic Society. Hyperbaric data from the original study reported in
the text was added to the ﬁgure by the authors.
greatest reductions in half-times. For example, a 70kg
patient ventilating at about 15–20lmin-1 (levels easily
tolerated by patients without severe lung disease) can
reduce the half-time to a value similar to that reported
for hyperbaric O2 (Takeuchi etal. 2000). Finally, the
relationship between minute ventilation and elimination
half-time is scalable to body size and sex (Tesler, 2000).
Back to carbogen?
Isitthereforeappropriatetoresurrectcarbogenasareadily
deployable means to increase alveolar ventilation without
reducing arterial PCO2? Unfortunately, it is not. As early as
1955, an ofﬁcial report to the Medical Research Council
(UK) (Donald & Paton, 1955) warned about the risk
of exacerbating acidosis by administering carbogen to
patients who are already retaining CO2 due to ventilatory
depression from severe CO poisoning or previously
ingested drugs. As for those patients with an intact
ventilatory response to CO2, administration of CO2 up
to a concentration of 4% increases the minute ventilation
only by a factor of two (Soley etal. 1941), thereby limiting
its effectiveness in CO elimination. Moreover, large
individual variations in ventilatory responses to inhaled
CO2 (Solely etal. 1941; Prisman etal. 2007) mean that
Figure 4. Half-time of COHb reduction versus minute
ventilation in humans
Seven men were exposed to CO until [COHb] reached 10–12% on
two separate occasions. On one occasion, subjects breathed 100% O2
(‘resting ventilation’). On the other occasion, subjects were
administered 100% O2 and asked to increase their minute ventilation;
on that occasion, isocapnia was maintained. Venous blood was drawn
every 5 min and analysed for [COHb]. Open symbols represent values
during resting ventilation (normobaric O2); ﬁlled symbols during
normocapnic hyperpnoea. Half-times of elimination were calculated
from plots of log [COHb] versus time. Most of the increase in [COHb]
reduction was reached at a relatively modest 200 ml min-1 kg-1,o r
141 min-1 for a 70 kg person. (From Takeuchi et al. 2000; reprinted
with permission of the American Thoracic Society. Copyright C  
American Thoracic Society.)
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Figure 5. A self-inﬂating bag circuit suitable for spontaneous
and controlled ventilation
Reserve gas enters circuit through the inspiratory relief valve of the
self inﬂating bag (modiﬁed from Fig. 1 of Sasano et al. 2001; ﬁgure
reproduced with permission of the publisher.)
onecannotguaranteeanincreasedrateofCOelimination,
or even that hypocapnia will be prevented (Baddeley
etal. 2000; Prisman etal. 2007). Above an inspired
CO2 concentration of 4%, minute ventilation markedly
increases, but so does respiratory distress (Baddeley etal.
2000); these investigators found that 30% of patients and
healthy subjects were unable to tolerate 5% CO2.I ti s
therefore unlikely that a single premixed carbogen dose
will ﬁt all.
Hyperpnoea without carbogen
It follows from the preceding discussion that exploiting
an increase in alveolar ventilation to clear the blood of
CO will require a different approach. The method used
must maintain normocapnia in order to allow patients to
sustain increased ventilation comfortably for two to three
half-times of CO elimination, thereby achieving more
complete elimination of CO. Rather than administering
a ﬁxed concentration of CO2 in an attempt to maintain
normocapnia with hyperpnoea, one can administer CO2
in direct proportion to increases in minute ventilation
above basal levels (Sommer etal. 1998). Ideally, the
apparatus that would be used to maintain normocapnia
would be safe, easy to use, portable and, if at all possible,
inexpensive.
Increasing alveolar ventilation while maintaining
normocapnia
Historically, the advances in treatment of CO poisoning
were also linked to the fabrication of devices required
to implement them. Henderson and Haggard in New
York devised their H-H Infusor to administer carbogen
(Henderson & Haggard, 1922). Smith and Sharp (1960)
builttheﬁrstﬁxedandthenportablehyperbaricchambers
(Norman etal. 1970) in the Aberdeen Royal Inﬁrmary, in
Scotland.Recently,researchersinourlaboratory(Sommer
etal. 1998) described a method that passively maintains
normocapniaregardlessofminuteventilationandpattern
ofbreathing.Inthatcircuit,aconstantO2 ﬂowisprovided
to a standard self-inﬂating bag, and the inspiratory relief
valve of the self-inﬂating bag is attached to a demand
regulatorsupplying6%CO2 inO2 (Fig.5).Anyincreasein
minuteventilationabovetheO2 ﬂowisthereforesupplied
by the demand regulator (6% CO2 in O2). The O2 ﬂow is
Figure 6. Data from a human subject to illustrate the effect of voluntary hyperventilation, without
(A) and with maintenance of normocapnia (B) with the breathing circuit depicted in Fig. 6, on
end-tidal PCO2
Lower panels show minute ventilation (˙ VE) and upper panels show continuous capnograph traces. Peaks are
end-tidal PCO2 and troughs represent inspired PCO2. Note proportional increases in inspired PCO2 as ˙ VE increases;
end-tidal PCO2 remains unchanged, regardless of ˙ VE.
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adjustedtomatchthepatient’smetabolicCO2 production
and controls the alveolar ventilation for CO2.A r t e r i a l
PCO2 isthereforeunchangedbyanyincreaseinventilation,
becauseanyventilationexceedingtheO2 ﬂowiscomposed
of 6% CO2 in O2, a mixture that does not contribute to
aC O 2 diffusion gradient between capillary blood and the
alveoli (Sommer etal. 1998; Somogyi etal. 2005; Fig.6).
However, it is the combined ﬂow of O2 and 6% CO2 in
O2 that serves to wash out CO from the lungs, thereby
clearing it from the blood.
The system is designed to be used in the ﬁeld, but
it cannot be readily improvised and requires deliberate
preparation. It requires a customized breathing circuit or
modiﬁcation of available self-inﬂating bags, compressed
CO2-containing gas with speciﬁc pressure regulator and
ﬂow controller. Such tanks require care in storage or
use in extreme cold because CO2 liqueﬁes readily when
cold. Use of the system requires some clinical expertise
or monitoring of end-tidal gas in order to set the fresh
gas ﬂow (O2 or air) appropriately to attain an appropriate
end-tidalPCO2.However,duetothebenignnatureofacute
hypercapniainadults(Potkin&Swenson,1992;Ayasetal.
1998), as well as in children (Goldstein etal. 1990), when
oxygenation is maintained, the fresh gas ﬂow need not be
exact and can be safely titrated to comfort or ventilatory
response, or can be set according to guidelines based on
approximate body weight.
Isocapnic hyperpnoea in practice
We suggest that the availability of a portable device to
increaseCOclearancewouldbeausefuladjuncttocurrent
treatment of CO poisoning. It can be brought to the
ﬁeld to begin treatment immediately at the time of rescue
andcontinuetreatmentduringtransportationtohospital.
The same device can be applied to patients breathing
spontaneously, as well as those requiring ventilatory
assistance. Prior CO clearance at the site of rescue would
make emergency air transport safer, should it be required.
Asnormocapniaismaintainedandtherearenoforeseeable
risks, this treatment can be administered on the suspicion
of CO poisoning. It would therefore provide the earliest
possibletreatmentifCOpoisoningislaterconﬁrmed,and
nothing is lost if it is not. Carbon monoxide poisoning
often occurs in clusters, and this treatment approach can
be inexpensively and safely applied to all victims. Finally,
early pulmonary CO clearance does not delay or preclude
anyothertreatment,includingsubsequenttreatmentwith
hyperbaric O2, if deemed necessary (Piantadosi, 2002;
Weaver etal. 2002).
It is also noteworthy that isocapnic increases in
alveolar ventilation with 21% O2 would be as effective
in eliminating CO as normobaric hyperoxia (Henderson
&Haggard,1920),yetavoidriskoftheadditionaloxidative
stress from hyperoxia. Furthermore, both hyperoxic and
normoxic isocapnic hyperpnoea would also accelerate the
clearance of any volatile hydrocarbons, including ethanol
(Henderson, 1924; Hunter & Mudd, 1924), methanol,
ingested poisons (Lemburg etal. 1979) and anaesthetic
agents (Sasano etal. 2001; Vesely etal. 2003; Katznelson
etal. 2008, 2010).
Summary
We believe we have now come full circle in the treatment
of CO poisoning. At the beginning of the 20th century,
carbogen proved to be an effective means of treating
CO poisoning. Only relatively recently was it realized
that it was not the CO2 in carbogen but the increase in
alveolar ventilation induced by the CO2 that accelerated
the clearance of CO. By then, however, rapid advances
in the technology of positive-pressure ventilation and
hyperbaric chambers overshadowed the old-fashioned
approach using carbogen. Despite the initial enthusiasm
for hyperbaric O2 as the treatment for CO poisoning, the
fact remains that hyperbaric O2 facilities are expensive
andtheirdistributionaroundtheworldispoorlymatched
to the incidence and prevalence of CO poisoning. Even
in wealthier urban areas, the inherent delays to initiate
treatment make them clinically ineffective. The technical
barriers to safely enable lung clearance of CO are low,
makingitfeasibletoprovideforwidespreadavailabilityof
themeansforearlyandrapidCOelimination.Inanycase,
early pulmonary CO clearance does not delay or preclude
anyothertreatment,includingsubsequenttreatmentwith
hyperbaric O2.
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